Open access · CC-BY
via OpenAlex
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Tessandra Stewart, Vesna Sossi, Jan Olav Aasly, Zbigniew K. Wszołek, Ryan J. Uitti, Kazuko Hasegawa, Teruo Yokoyama, Cyrus P. Zabetian, James B. Leverenz, Alexander Jon Stoessl, Yu Wang, Carmen Ginghină, Changqin Liu, Kevin C. Cain, Peggy Auinger
Acta Neuropathologica Communications · 2015 · ▲ 99 citations
Abstract
INTRODUCTION: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers). RESULTS: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages. CONCLUSION: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s40478-015-0185-3
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Stewart, T., Sossi, V., Aasly, J.O., Wszołek, Z.K., Uitti, R.J., Hasegawa, K., Yokoyama, T., Zabetian, C.P., Leverenz, J.B., Stoessl, A.J., Wang, Y., Ginghină, C., Liu, C., Cain, K.C., Auinger, P., Kang, U.J., Jensen, P.H., Shi, M.Y., & Zhang, J. (2015). Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity. <em>Acta Neuropathologica Communications</em>. https://doi.org/10.1186/s40478-015-0185-3
Vancouver
Stewart T, Sossi V, Aasly JO, Wszołek ZK, Uitti RJ, Hasegawa K, et al. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathologica Communications. 2015. doi:10.1186/s40478-015-0185-3.
BibTeX
@article{tessandra2015Phosph,
title = {Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity},
author = {Tessandra Stewart and Vesna Sossi and Jan Olav Aasly and Zbigniew K. Wszołek and Ryan J. Uitti and Kazuko Hasegawa and Teruo Yokoyama and Cyrus P. Zabetian and James B. Leverenz and Alexander Jon Stoessl and Yu Wang and Carmen Ginghină and Changqin Liu and Kevin C. Cain and Peggy Auinger and Un Jung Kang and Poul Henning Jensen and Min Yan Shi and Jing Zhang},
journal = {Acta Neuropathologica Communications},
year = {2015},
doi = {10.1186/s40478-015-0185-3},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Qatar Foundation Annual Research Conference (ARC) 2016
Citation only
Alpha-Synuclein Oligomers as a Biomarker Candidate for Parkinson's Disease and Disorders
PLoS ONE 2016
Open access · CC-BY
Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson’s Disease
Frontiers in Neurology 2020
Open access · CC-BY
Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
Age and Ageing 2016
Open access · OA
Moving upstream in the frailty trajectory
Frontiers in aging neuroscience 2026
Citation only
Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
2026
Preprint